Should I buy or sell Alnylam Pharmaceuticals stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALNY shares. View ALNY analyst ratings or view top-rated stocks .

What is Alnylam Pharmaceuticals' stock price target for 2024?

19 brokers have issued 1 year target prices for Alnylam Pharmaceuticals' stock. Their ALNY share price targets range from $143.00 to $395.00. On average, they predict the company's stock price to reach $233.00 in the next twelve months. This suggests a possible upside of 31.5% from the stock's current price. View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts .

How have ALNY shares performed in 2023?

Alnylam Pharmaceuticals' stock was trading at $237.65 at the beginning of 2023. Since then, ALNY stock has decreased by 25.4% and is now trading at $177.19. View the best growth stocks for 2023 here .

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our ALNY earnings forecast .

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of ($1.61) by $2.76. The biopharmaceutical company had revenue of $750.53 million for the quarter, compared to analyst estimates of $406.14 million.

What ETFs hold Alnylam Pharmaceuticals' stock?

ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR) , ETFMG Treatments Testing and Advancements ETF (GERM) , Global X Genomics & Biotechnology ETF (GNOM) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Horizon Kinetics Medical ETF (MEDX) , Fidelity Disruptive Medicine ETF (FMED) , VanEck Biotech ETF (BBH) and Principal Healthcare Innovators ETF (BTEC) .

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com . John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA) , NVIDIA (NVDA) , XOMA (XOMA) , Ionis Pharmaceuticals (IONS) , Gilead Sciences (GILD) , NXP Semiconductors (NXPI) , Mylan (MYL) , AbbVie (ABBV) , Micron Technology (MU) and Advanced Micro Devices (AMD) .

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (6.51%), Wellington Management Group LLP (5.13%), Northern Trust Corp (0.64%), Legal & General Group Plc (0.63%), Ameriprise Financial Inc. (0.56%) and Massachusetts Financial Services Co. MA (0.55%). Insiders that own company stock include Akshay Vaishnaw , Indrani Lall Franchini , Jeffrey V Poulton , Jeffrey W Dunn , John Maraganore , Laurie Keating , Pushkal Garg , Steven M Paul , Tolga Tanguler and Yvonne Greenstreet . View institutional ownership trends .

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Most-Downgraded StocksMost-Downgraded

Alnylam Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ALNY)

$176.45

+1.43 (+0.82%)

(As of 02:20 PM ET)

Compare

Today's Range: $174.39
▼
$177.77
50-Day Range: $151.41
▼
$178.96
52-Week Range: $148.10
▼
$242.97

Volume: 252,747 shs
Average Volume: 671,963 shs
Market Capitalization: $22.14 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $233.00

Alnylam Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.68 Rating Score
Upside/Downside: 31.5% Upside
$233.00 Price Target
Short Interest: Healthy
4.14% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.52
Upright™ Environmental Score
News Sentiment: 0.99
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.74) to ($5.15) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

133rd out of 958 stocks

Pharmaceutical Preparations Industry

31st out of 393 stocks

4.3

Analyst's Opinion

Consensus Rating
Alnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 13 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $233.00, Alnylam Pharmaceuticals has a forecasted upside of 31.5% from its current price of $177.19.
Amount of Analyst Coverage
Alnylam Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
4.14% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 8.
Change versus previous month
Short interest in Alnylam Pharmaceuticals has recently decreased by 1.52%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Alnylam Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Alnylam Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Alnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Alnylam Pharmaceuticals is -1.52.

3.3

News and Social Media Coverage

News Sentiment
Alnylam Pharmaceuticals has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Alnylam Pharmaceuticals this week, compared to 8 articles on an average week.
Search Interest
Only 5 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
3 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alnylam Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.40% of the stock of Alnylam Pharmaceuticals is held by insiders.
Percentage Held by Institutions
93.98% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Alnylam Pharmaceuticals are expected to decrease in the coming year, from ($3.74) to ($5.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alnylam Pharmaceuticals is -42.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alnylam Pharmaceuticals is -42.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALNY Stock News Headlines

December 6, 2023 | stocknews.com

3 Solid Biotech Buys for a Healthy Year-End Portfolio

December 5, 2023 | in.investing.com

Pro Research: uncovering the potential of Wall Street's biotech star

December 7, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

December 4, 2023 | au.investing.com

Pro Research: Wall Street delves into Alnylam Pharmaceuticals

December 2, 2023 | americanbankingnews.com

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Analysts

December 1, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: UnitedHealth (UNH), Alnylam Pharma (ALNY)

November 30, 2023 | finance.yahoo.com

Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023

November 29, 2023 | benzinga.com

Alnylam Pharmaceuticals Stock (NASDAQ:ALNY) Dividends: History, Yield and Dates

December 7, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 29, 2023 | msn.com

Alnylam Pharmaceuticals tops list of largest companies for the third year

November 15, 2023 | markets.businessinsider.com

Promising Future for Milestone Pharmaceuticals: Buy Rating Reaffirmed Amid Encouraging Etripamil Trial Outcomes and Projected Revenue Growth

November 13, 2023 | seekingalpha.com

Alnylam: Q3 Journey, Financial Growth, And Regulatory Hurdles

November 13, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Exelixis (EXEL), Hologic (HOLX) and Alnylam Pharma (ALNY)

November 13, 2023 | msn.com

Alnylam reports positive Phase 2 data for hypertension drug

November 11, 2023 | businesswire.com

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of ...

November 11, 2023 | finance.yahoo.com

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

November 10, 2023 | markets.businessinsider.com

Oppenheimer Keeps Their Hold Rating on Teva Pharmaceutical (TEVA)

November 9, 2023 | finance.yahoo.com

Alnylam Pharmaceuticals, Inc.: Alnylam Earnings: Strong Demand for Amvuttra Drives Sales; Shares Undervalued

November 8, 2023 | finance.yahoo.com

Wall Street Analysts Think Alnylam (ALNY) Could Surge 35.08%: Read This Before Placing a Bet

November 6, 2023 | markets.businessinsider.com

Hold Rating on Alnylam Pharma: Q3 Performance, Pipeline Prospects, and Regulatory Challenges

November 6, 2023 | markets.businessinsider.com

Alnylam Pharma: Promising Revenue and Pipeline Updates Inspire Buy Rating Despite Lowered Price Target

November 4, 2023 | finance.yahoo.com

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2023 Earnings Call Transcript

November 4, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), COMPASS Pathways (CMPS)

November 4, 2023 | markets.businessinsider.com

Buy Rating for Alnylam Pharma: Key Catalysts and Promising Pipeline Programs

November 2, 2023 | markets.businessinsider.com

Alnylam Pharmaceuticals Inc. Q3 Earnings Summary

November 2, 2023 | msn.com

Alnylam Pharmaceuticals beats Q3 top and bottom line estimates; updates FY23 outlook

November 2, 2023 | finance.yahoo.com

Alnylam (ALNY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

See More Headlines

Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ALNY
CUSIP: 02043Q10
CIK: 1178670
Web: www.alnylam.com
Phone: (617) 551-8200
Fax: 617-551-8101
Employees: 2,002
Year Founded: 2002

Price Target and Rating

Average Stock Price Target: $233.00
High Stock Price Target: $395.00
Low Stock Price Target: $143.00
Potential Upside/Downside: +33.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.68
Research Coverage: 19 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,131,160,000.00
Net Margins: -29.58%
Pretax Margin: -29.17%
Return on Equity: N/A
Return on Assets: -14.38%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.14
Quick Ratio: 3.04

Sales & Book Value

Annual Sales: $1.04 billion
Price / Sales: 21.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.29) per share
Price / Book: -135.67

Miscellaneous

Outstanding Shares: 125,490,000
Free Float: 123,736,000
Market Cap: $21.96 billion
Optionable: Optionable
Beta: 0.50

Social Links

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Yvonne L. Greenstreet M.B.A. (Age 60)
MBChB, CEO & Director
Comp: $2.09M
Mr. Jeffrey V. Poulton M.B.A. (Age 55)
CFO & Executive VP
Comp: $972.35k
Ms. Indrani M. Lall Franchini J.D. (Age 51)
Executive VP, Chief Legal Officer & Secretary
Comp: $958.96k
Dr. Akshay K. Vaishnaw M.D. (Age 60)
Ph.D., Chief Innovation Officer
Comp: $1.24M
Dr. Pushkal P. Garg M.D. (Age 55)
Chief Medical Officer and Executive VP of Development & Medical Affairs
Comp: $1M
Mr. Timothy J. Maines
Chief Technical Operations & Quality Officer
Dr. Kevin Joseph Fitzgerald Ph.D. (Age 55)
Senior VP, Head of Research & Chief Scientific Officer
Ms. Christine Regan Lindenboom (Age 42)
Senior VP of Investor Relations & Corporate Communications
Mr. Piyush Sharma J.D.
Chief Ethics & Compliance Officer
Mr. Evan Lippman
Chief Corporate Development & Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Alnylam Pharmaceuticals was last updated on Tuesday, November 28, 2023 at 10:13 PM.

Pros

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

Strong pipeline of investigational RNAi therapeutics targeting various diseases, including genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases.
Marketed products such as ONPATTRO, GIVLAARI, and OXLUMO have shown promising results in treating specific conditions, providing potential revenue streams.
Strategic collaborations with Regeneron Pharmaceuticals, Sanofi Genzyme, and other companies enhance the company's research and development capabilities and market reach.
Ongoing clinical trials for products like givosiran, patisiran, and vutrisiran offer potential for future product approvals and market expansion.
Recent positive developments and partnerships indicate a strong growth trajectory for the company.

Cons

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which may impact the company's ability to bring products to market.
Investing in biopharmaceutical companies carries inherent risks, including clinical trial failures, regulatory setbacks, and intellectual property disputes.
Market volatility and economic uncertainties can affect the company's stock price and overall financial performance.
Dependency on successful product launches and commercialization efforts for revenue generation.
Potential impact of healthcare reforms and changes in reimbursement policies on the company's financials.

ALNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?: 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALNY shares.
View ALNY analyst ratings or view top-rated stocks.
What is Alnylam Pharmaceuticals' stock price target for 2024?: 19 brokers have issued 1 year target prices for Alnylam Pharmaceuticals' stock. Their ALNY share price targets range from $143.00 to $395.00. On average, they predict the company's stock price to reach $233.00 in the next twelve months. This suggests a possible upside of 31.5% from the stock's current price.
View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts.
How have ALNY shares performed in 2023?: Alnylam Pharmaceuticals' stock was trading at $237.65 at the beginning of 2023. Since then, ALNY stock has decreased by 25.4% and is now trading at $177.19.
View the best growth stocks for 2023 here.
When is Alnylam Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our ALNY earnings forecast.
How were Alnylam Pharmaceuticals' earnings last quarter?: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of ($1.61) by $2.76. The biopharmaceutical company had revenue of $750.53 million for the quarter, compared to analyst estimates of $406.14 million.
What ETFs hold Alnylam Pharmaceuticals' stock?: ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), Fidelity Disruptive Medicine ETF (FMED), VanEck Biotech ETF (BBH) and Principal Healthcare Innovators ETF (BTEC).

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?: 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Alnylam Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).
Who are Alnylam Pharmaceuticals' major shareholders?: Alnylam Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (6.51%), Wellington Management Group LLP (5.13%), Northern Trust Corp (0.64%), Legal & General Group Plc (0.63%), Ameriprise Financial Inc. (0.56%) and Massachusetts Financial Services Co. MA (0.55%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends.
How do I buy shares of Alnylam Pharmaceuticals?: Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALNY) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial